The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder. [electronic resource]
Producer: 20180116Description: 603-11 p. digitalISSN:- 1461-7285
- Adult
- Antidepressive Agents, Second-Generation -- adverse effects
- Antidepressive Agents, Tricyclic -- adverse effects
- Antipsychotic Agents -- adverse effects
- Body Dysmorphic Disorders -- diagnosis
- Brazil
- Clomipramine -- adverse effects
- Comorbidity
- Drug Therapy, Combination
- Female
- Fluoxetine -- adverse effects
- Humans
- Male
- Obsessive-Compulsive Disorder -- diagnosis
- Prospective Studies
- Quetiapine Fumarate -- adverse effects
- Risk Factors
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.